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Abstract
Background: The use of integrating viral vectors in Gene therapy clinical trials has pointed out
the problem of the deleterous effect of the integration of the ectopic gene to the cellular genome
and the safety of this strategy. We proposed here a way to induce the death of gene modified cells
upon request by acting on a pro-apoptotic protein cellular localization and on the activation of its
apoptotic function.
Results: We constructed an adenoviral vector coding a chimeric p53 protein by fusing p53
sequence with the 21 COOH term amino acids sequence of H-Ras. Indeed, the translation
products of Ras genes are cytosolic proteins that become secondarily associated with membranes
through a series of post-translational modifications initiated by a CAAX motif present at the C
terminus of Ras proteins. The chimeric p53HRCaax protein was farnesylated efficiently in
transduced human osteosarcoma p53-/- cell line. The farnesylated form of p53 resided mainly in
the cytosol, where it is non-functional. Farnesyl transferase inhibitors (FTIs) specifically inhibited
farnesyl isoprenoid lipid modification of proteins. Following treatment of the cells with an FTI,
p53HRCaax underwent translocation into the nucleus where it retained transcription factor
activity. Shifting p53 into the nucleus resulted in the induction of p21waf1/CIP1 and Bax transcription,
cell growth arrest, caspase activation and apoptosis.
Conclusion: Artificial protein farnesylation impaired the transcriptional activity of p53. This could
be prevented by Farnesyl transferase inhibition. These data highlight the fact that the artificial
prenylation of proteins provides a novel system for controlling the function of a transactivating
factor.
Background
One of the common obstacles encountered in gene ther-
apy trials is the potential deleterious effect of the integra-
tion of the ectopic gene to the cellular genome. As an
example a serious adverse event after successful gene ther-
apy for X-linked severe combined immunodeficiency has
been described with a LMO2-associated clonal T cell pro-
liferation in two patients [1,2]. A way to eradicate this neg-
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ative effect is to induce the death of the modified cells
upon request including a suicide gene in the gene transfer
vector. Previous approaches used gancyclovir-induced cell
death post transduction with a viral vector containing a
Herplex Simplex Virus-Thymidine kinase expression cas-
sette [3]. However the effectiveness of this strategy may be
blunted because of their more limited effect on quiescent
or slowly dividing cells that require prolonged expression
of the therapeutic gene and long term administration of
the prodrugs. Another way to induce the death of gene
modified cells is to promote expression of a pro-apoptotic
protein, a cytotoxic protein or a drug sensitive inducer
protein such as CD20 as suggested recently [4] via a phar-
macological control of the transgene transcription [5,6].
Transcription regulation is usually achieve by means of
cell-permeant-inducing agents such as tetracycline, mac-
rolides, oestrogen, progesterone, isopropyl-b-D-thioga-
lactoside and ectysone [7,8]. Here we proposed a post
translational control of a protein. We studied a way to
pharmacologically induce protein function upon request
by reversible sub-cellular localization of the protein.
Protein prenylation is required for the biological func-
tions of several proteins by permitting association with
the cell membranes and encouraging protein-protein
interactions with other regulatory molecules. Protein iso-
prenylation is a post translational isoprenoid lipid modi-
fication of substrate proteins by isoprenic lipids [9]. 0.5 to
1 % of cellular proteins are isoprenylated (for review[10]),
including members of the RasGTPase superfamily, several
protein kinases and phosphatases, and a variety of pro-
teins involved in nuclear integrity and centromere func-
tion [10-12]. Two type of enzymes catalyse protein
isoprenylation, the CAAX prenyl transferase, farnesyl
transferase (FTase) and Geranylgeranyl transferase I
(GGTaseI) that recognize CAAX (A is aliphatic and X is
any amino acid) C terminus peptide motif and rabGGTase
or GGTaseII that recognizes CCX or CXC C terminus
motifs. FTase or GGTaseI catalyse the covalent attachment
of the 15 carbon farnesyl or the 20 carbon geranylgeranyl
respectively to the cysteine of the CAAX motif. The termi-
nal X residue of the CAAX motif determines whether far-
nesylation or geranylgeranylation occurs: FTase prefers X
to be methionine, serine, alanine or glutamine, as for Ras
proteins [13] while GGTaseI prefers leucine or isoleucine.
There are exceptions to this general rule since RhoB can be
farnesylated or geranylgeranylated in vivo by FTase and
GGTaseI respectively [14] and since N-Ras or K-Ras but
not H-Ras can be geranylgeranylated by GGTaseI when
the FTase is inhibited. Protein prenylation is the first step
of a complex protein processing including proteolytic
cleavage of the AAX peptide, carboxymethylation of the
prenylated cysteine residue, and lastly for some proteins,
attachment of a palmitate residue near the prenylated
cysteine. The development of FTase inhibitors (FTIs) has
raised the possibility of specifically inhibiting the func-
tion of proteins involved in oncogenesis such as Ras onco-
proteins. By preventing Ras farnesylation, FTIs severely
impair Ras functions because of the inability of the non
farnesylated protein to anchor to the membranes [15].
FTIs are currently under evaluation in phase II/III clinical
trials for the treatment of cancer [16] and show relatively
low-toxic effects [9].
We recently showed that a artificial three-component chi-
maera consisting of the ribosome recruitment core of the
eIF4G1 eukaryotic translation factor, the RNA-binding
domain of the R17 bacteriophage coat protein and the
plasma membrane localization CAAX motif of far-
nesylated H-Ras can have its translational activity inhib-
ited through protein farnesylation that could be restored
by FTI treatment. This result put on light the possibility of
a pharmacological switche that control gene expression at
the translational level [17]. Here, we hypothezize that this
concept could be applied to control the proteins that exert
their functions in specific cellular compartment such as
nuclear transcriptional factor as p53.
The gene encoding p53 mediates a major tumor suppres-
sion pathway that is frequently altered in human cancers
[18]. P53 is inhibited during normal cell growth by
MDM2 a proto-oncogene through either ubiquitin-
dependent p53 degradation in the cytoplasm or repres-
sion of the transcriptional activity of p53 in the nucleus
[19]. P53 is activated following cellular stresses leading to
its phosphorylation and translocation to the nucleus.
Nuclear activated p53 binds to specific DNA sequences
and triggers the transcription of target genes thus func-
tionning, at least in part, as a transcriptional regulator.
P53 contributes to tumor suppression through at least two
mechanisms, arrest of cell proliferation [20] and induc-
tion of cell death through apoptosis [21].
The aim of this study was to find a way to induce the death
(here by apoptosis) of targeted cells upon request. The
way that has been chosen is to control the function of a
protein (here a transcriptional factor, p53) by acting on its
localization. To inactivate p53 function we targeted it to
the cell membranes by post translational modifications.
We have generated a chimeric p53 protein with the 21
COOH term amino acids of H-Ras (HRCaax) fused to the
COOH term of p53. We have demonstrated that an inac-
tive chimeric p53HRCaax gains its cellular functions in
SaOs-2 cells (activation of p21waf1/CIP1 and Bax transcrip-
tion, growth arrest and apoptosis) under FTI treatment.
These data highlight the fact that the artificial prenylation
of proteins provide a novel system for controlling the
function of a transactivating proteins.BMC Biotechnology 2006, 6:26 http://www.biomedcentral.com/1472-6750/6/26
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Results
The SaOs-2 human osteosarcoma is a poorly differenti-
ated, growth factor-insensitive cell line. This p53-/- cell
line was selected because an ectopic expression of p53
induces their apoptosis [22].
Several Ad vectors encoding different mutated forms of
the pro-apoptotic gene p53 were constructed to transduce
these SaOs-2 cells. In this study, our aim was to compare
the efficiency of mutated form of p53 versus wtp53 in
inducing cellular responses, such as apoptosis only in the
presence of FTI.
Adenoviral vectors have been constructed to efficiently
transduce SaOs-2 cells. The proapoptotic genes were
under the transcriptional control of the strong CMV pro-
moter. We generated Adp53wt, Adp53HRCaax in which
the TGA codon of the p53 coding gene has been replaced
by the sequence encoding 21 COOH term amino acids of
H-Ras which correspond to the membrane binding
domain of H-Ras allowing the whole post translational
processing of the protein, and Adp53HRSaax as a control.
In this control vector, the TGA codon of the p53 coding
gene has been replaced by the sequence encoding 21
COOH term amino acids of H-Ras with a single base
mutation allowing the translation of a serine instead of a
cysteine in the CAAX motif of the chimeric protein. This
p53HRasSAAX is unable to be processed. Brand et al [23]
showed that in vitro ∆E1 Ad vector could lead to growth
retardation, prolongation of the G2/M phase and induc-
tion of apoptosis if applied at a high MOI. To distinguish
between the cytotoxicity of the vectors and the effect of the
transgene we compared the vectors mentioned above with
either AdeGFP (enhanced Green Fluorescent Protein) or
AdLuc (Luciferase). Using AdeGFP, we confirmed that
more than 95% of the cells were GFP positive when using
100 physical particles/cell and no significant cytotoxicity
was seen 7-days post transduction (data not shown).
These data demonstrated, under our conditions, that cell
responses observed bellow were due to transgene expres-
sion and that modest doses of vectors led to efficient
transduction.
Ad transduced SaOs-2 cells could express the farnesylated 
form of p53
Forty eight hr post transduction of SaOs-2 cells by the dif-
ferent Ad vectors, cells extracts were analyzed by Western
blot (Fig. 1). As expected, AdLuc transduced cells did not
express p53 protein. Following transduction with
Adp53wt, Adp53HRCaax or Adp53HRSaax, p53 protein
expression was observed. These results are consistent with
expression of the ectopic p53 gene. All p53 mutants were
expressed roughtly at the same level. Moreover, treatment
of the cells with FTI did not induce any variation of the
p53 expression irrespective of the form tested. Several pro-
teins, aside from the Ras family are known to be far-
nesylated. These farnesylated proteins may be useful
surrogate markers for determining whether a specific FTI
is actually inhibiting farnesylation, by providing an indi-
rect measure of FTase inhibition. Example of these pro-
teins include HDJ-2, a chaperone protein. The inhibition
of farnesylation of HDJ-2 can be monitored by immuno-
blotting, since its unfarnesylated form displays a reduced
mobility in SDS-PAGE relative to its farnesylated versions
Expression of ectopic p53 and endogenous HDJ-2 in human SaOs-2 cells Figure 1
Expression of ectopic p53 and endogenous HDJ-2 in human SaOs-2 cells. Cells were transduced with adenoviral vec-
tors expressing the indicated p53 proteins or luciferase as a control. Total protein extracts (80 µg) of SaOs-2 cultures trans-
duced with different Ad-vectors and untreated (-) or treated (+) with 15 µM FTI were prepared 48 hr post transduction and 
analysed by immunoblotting employing the anti-p53 (1:500) and anti HDJ-2 (1:1000) antibodies.
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[24]. When SaOs-2 transduced cells were exposed to 15
µM FTI-277, a mobility shift on SDS-PAGE was observed
in HDJ-2, reflecting inhibition of FTase. Moreover, a slight
mobility shift in the P53HRCaax band was noted, suggest-
ing that FTI-277 prevents the protein farnesylation of this
mutant (Fig. 1).
Hras membrane binding domain induced p53 membranes 
localization
The sub-cellular localization of the different P53 mutants
was analyzed 48 hr post transduction of SaOs-2 cells by
the different Ad vectors (Figure 2A).
Transducing the cells with Adp53HRCaax resulted in a
distinctive, punctuate staining pattern in the cytosol with
a perinuclear concentration (Adp53HRCaax) excluding
the nucleus. Confocal imaging confirmed that
p53HRCaax was perinuclear and cytoplasmic (Figure 2B).
In the presence of 15 µM FTI, Adp53HRCaax transduced
SaOs-2 cells expressed p53 exclusively in the nucleus sug-
gesting that inhibition of farnesylation of p53 abolished
its membranes sequestration.
Mihara et al [25] recently reported that a fraction of stess-
induced wild-type p53 translocates to mitochondria dur-
ing p53 dependent apoptosis after DNA damage and
under hypoxia. We have shown here that the farnesylated
form of p53 did not localize preferentially to the cell
plasma membrane as expected. Therefore we checked by
confocal microscopy whether p53HRCaax could localize
to the mitochondria in the absence of FTI by colocaliza-
tion with mitochondrial markers (mitotraker red). Just as
wtp53, p53HRCaax did not translocate to the mitochon-
dria in the transduced SaOs-2 cells either 24 or 48 hr post
transduction (data not shown).
As a control, when Adp53wt or Adp53HRSaax transduced
cells were stained, a nuclear localization of p53 was
observed irrespective of whether the cells are untreated or
treated or not with FTI (Adp53wt, Adp53HRSaax). Cul-
Subcellular localization of p53 in the different transduced and FTI-treated SaOs-2 cells Figure 2
Subcellular localization of p53 in the different transduced and FTI-treated SaOs-2 cells. A: AdLuc, Adp53wt, 
Adp53HRSaax, or Adp53HRCaax transduced SaOs-2 cells were untreated or treated with 15 µM FTI for 24 hr. They were 
then stained with the FITC-conjugated anti human p53 antibody (1:100) and DAPI = 4',6'-diamino-2-phenylindole. The subcel-
lular localization of p53 was examined microscopically. B: Confocal microscopy of transduced Adp53wt or Adp53HRCaax cells 
treated with FTI for 24 hr.
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p53-mediated transcriptional transactivation Figure 3
p53-mediated transcriptional transactivation. A : p53-mediated transcriptional transactivation as determined by luci-
ferase activity in SaOs-2 cells co-transfected with a p53-responsive promoter luciferase plasmid and a renilia luciferase expres-
sion plasmid for transfection efficiency. Cells were then transduced with the indicated p53 adenoviral vectors. Cell extracts 
from each triplicate were assayed for both firefly and Renilla luciferases. Results are expressed as the ratio of activity of the fire-
fly to the Renilla luciferase. The average mean +/- SD values and the induction factor relative to the transfection-containing no 
viral vector from two sets of experiments with triplicate transfections are shown. B: Relative levels of p21waf1/CIP1 protein were 
measured by immunoblot assay using lysates (80 µg) prepared from SaOs-2 expressing luciferase (mock), p53wt, or 
p53HRCaax cultured for 48 hr in the presence (+) or absence (-) of the FTI (15 µM). C : Relative levels of Bax protein were 
measured by immunoblot assay using lysates (80 µg) prepared from SaOs-2 expressing luciferase (mock), p53wt, or 
p53HRCaax and cultured for 48 hrs in the presence (+) or absence (-) of the FTI (15 µM). One representative of three differ-
ent experiments is shown.
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ture with FTI had no effect on p53 localization for these
p53 forms.
The farnesylated form of p53 (p53HRCaax) had reduced 
transactivation activity
The tumor suppressor activity of p53 is related to its abil-
ity to interact with both DNA and proteins. As a result of
complex patterns of both DNA-protein and protein-pro-
tein interactions, expression of the down-stream genes
that participate in the control of DNA replication, repair,
cell cycle and apoptosis can be either elevated or
decreased by p53. We have used a reporter gene assay to
analyse the transcriptional activity of the different p53
mutants using the reporter vector pGL3-in which the luc
reporter gene is driven by a promoter that is sensitive to
induction by p53. It is anticipated that the expression of
the luciferase gene will be enhanced in the presence of a
functional p53. Using the polyethylenimine (PEI)
method, we transiently transfected the p53-/- cells SaOs-2
with this Luc gene as reporter, plus a renilia luciferase
expression plasmid to control transfection efficiency.
Then, these cells were transduced with the different Ad
vectors in the presence or absence of 15 µM FTI. Both LucF
and LucR activities were measured. As shown in Figure 3A,
p53-mediated transcriptional transactivation was effective
in cells transduced with either Adp53wt or Adp53HRSaax
in the presence or absence of FTI. In contrast, p53-medi-
ated transcriptional transactivation was effectively low-
ered in p53HRCaax transduced cells, although FTI-277
treatment restored the transactivation efficiency of the
p53HRCaax mutant.
We then analysed the induction of the p53 endogenous
target genes, p21waf1/CIP1 and Bax. Western blotting was
performed for p21waf1/CIP1 and Bax to detect functional
p53 activity in cells with and without exposure to the dif-
ferent vectors in the presence or absence of the FTI. As
expected p53wt, but not p53HRCaax transduced cells
expressed p21waf1/CIP1 within 48 hr of transduction (Fig.
3B). Both cells expressed Bax at different levels (Fig. 3C).
FTI treatment induced p21waf1/CIP1 expression or a higher
level of Bax expression in p53HRCaax cells, while no
modification of protein levels was observed in Adp53wt
transduced cells. (Figs. 3B and 3C).
Overall these data demonstrated that the HRCaax domain
fused with the p53 protein impaired the transcriptional
transactivation function of the protein, although this
could be reinduced by farnesyl transferase inhibition.
FTI triggered cell growth inhibition and apoptosis of the 
p53HRCaax mutant
The p53 protein is a potent inhibitor of cell growth, arrest-
ing the cell cycle at several points and, under certain cir-
cumstances, activating the apoptotic machinery leading to
cell death [26]. To compare the antiproliferative activity of
wtp53, p53HRCaax and p53HRSaax, cell viability was
determined using an MTT assay at 24, 48, 72 and 96 hr
In vitro assessment of the antiproliferative effect of the chimeric p53 genes Figure 4
In vitro assessment of the antiproliferative effect of the chimeric p53 genes. Cell viability determined by colorimet-
ric assay with MTT after transduction.
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post-transduction by the different Ad vectors. SaOs-2 cells
transduced with Adp53wt, Adp53HRSaax in the presence
or absence of FTI or those transduced with Adp53HRCaax
plus the FTI all showed a similar level of cell death. In con-
trast SaOs-2 cells transduced with Adp53HRCaax in the
absence of the FTI were more resistant to cell death (Fig.
4).
To quantify the apoptosic effects, Annexin V-positive pop-
ulations were estimated by fluorescence microscopy at
various times after transduction (Fig. 5). Transdution of
cells with Adp53HRCaax in the absence of FTI resulted in
only background levels of apoptotic cells, similar to those
of mock tranduction. In contrast, Adp53HRCaax in the
presence of FTI induced the apoptosis of more than 80 %
of SaOs-2 cells, as seen with Adp53wt. Transduction of
cells with AdLuc resulted in only a a very few apoptotic
cells, such as in the non transduced cells.
Therefore, we have shown that the farnesylated form of
p53 elicits no apoptosis of SaOs-2 in the absence of the
FTI. Yet the ability to elicit apoptosis could be restored in
the presence of the FTI.
Discussion
We have shown that the artificial prenylation of proteins
could provide a novel system for controlling the function
of a protein such as here a transactivating factor. The far-
nesylation of a protein changed its cellular localization
therefore its function was inhibited. This post transla-
tional modification could be prevented by inhibition of
farnesyl transferase leading to protein activation. These
new properties of an ectopic protein could be used to
develop a 'gain of function' approach designed to allow
the death by apoptosis of targeted gene modified cells
upon request. To prove the concept we have chosen to use
p53 as it is a tumor suppressor gene involved in cell cycle
arrest and programmed cell death (apoptosis). The prop-
erties of p53 are mainly linked to its ability to induce the
transcription of genes, such as the cyclin-dependent
kinase inhibitor p21waf1/CIP1  or Bax [27,28]. We con-
structed a p53 chimeric protein which is a substrate for
farnesyl transferase by fusing the membrane binding
Proportion of cells expressing markers of apoptosis 48 hr post transduction with the adenoviral vectors Figure 5
Proportion of cells expressing markers of apoptosis 48 hr post transduction with the adenoviral vectors. Sam-
ples of cells were stained with annexin V-FITC 48 hr post transduction to detect externalized phosphatidylserine. Apoptosis in 
expressing cells was quantitated by FITC staining, counting 20 random microscopic fields. One representative experiment from 
a total of three is shown. Percentage of apoptotic cells was determined microscopically. Values are the means +/- SD of three 
different experiments.
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domain of H-Ras that includes the 21 COOH term amino
acids of the protein to the COOH end of p53. We used this
domain because, in contrast to N-Ras and K-Ras, H-Ras
membrane binding domain is not a substrate of GGTaseI
when FTase is inhibited. This eliminates the possibility of
protein geranylgeranylation under FTI treatment. We have
demonstrated that it is the C terminus membrane binding
domain of H-Ras, but not that of the CAAX box permitting
only farnesylation which avoids nuclear localization of
the p53 transcriptional factor (data not shown). This
highlight the fact that only farnesylation is not sufficient
to induce membrane attachment of a chimeric protein
and that complete post translational processing is neces-
sary for this purpose.
The post translational modification of the chimeric p53
protein is illustrated by a slight shift of the farnesylated
form of the p53 protein, as observed in the Figure 1. We
have verified that the non processed form of the H-Ras
binding domain p53 chimeric protein does not impair its
transcriptional activity. Indeed, p53HRSaax, like
p53HRCaax in the presence of the FTI, was able to induce
transcription of responder genes as efficiently in vitro as in
vivo and was also able to induce apoptosis of the SaOs-2
cells.
P53 shuttles within the cell between the nucleus and the
cytoplasm, possessing nuclear localization signals (NLS)
and a nuclear export signal (NES) [29]. It was a challenge
to impede the nuclear translocation of a protein contain-
ing an NLS domain and this was achieved by lipid modi-
fication which avoids nuclear localization of the p53
transcriptional factor. This highlights the possibility of
developing this strategy so as to control the protein func-
tion of other nuclear proteins. We have shown here that
the lipid processed form of p53 whilst located in part in
the plasma membrane, was found preferentially in the
cytoplasm. This observation is not surprising since Chiu et
al [15] have shown that farnesylation of the CAAX motif
could also target Ras proteins to the endoplasmic reticu-
lum and Golgi membranes. In these locations they
encounter Rce protease and prenylcysteine-directed car-
boxymethyltransferase. Thus nascent Ras proteins are
present, at least transiently, on the endoplasmic reticulum
and Golgi. The fact that farnesylation could control cellu-
lar localization of different chimeric protein (farnesylated
form of eGFP) has also been described previously [30,31].
We have used farnesylation of p53 to control its localiza-
tion and therefore it's function. We have shown here that
bypassing the nucleus by targeting p53 to other cell com-
partments is sufficient to significantly reduce the marked
apoptosis of p53-deficient tumor cells in the absence of an
FTI. This therefore establishes the proof of principle that a
chimeric p53 can initiate apoptosis only upon treatment
of cells with the FTI,.
FTIs have previously demonstrated low toxicity in normal
cells. Several FTIs are currently being evaluated in phase II
and phase III clinical trials [9,32]. FTIs can exert dramatic
effects on cancer cells, including morphological changes,
inhibition of anchorage-independent growth and altera-
tion of cell cycle progression. Although FTIs clearly inhibit
Ras farnesylation it is unclear whether their antiprolifera-
tive effects result exclusively from their inhibition of Ras
functioning [16]. FTIs have effects on several other pre-
nylated proteins involved in crucial cellular signal trans-
duction pathways, such as the centromere binding protein
(CENP)-E and CENP-F, peroxysomal membrane and
nuclear membrane (lamin A and B) associated proteins,
or members of the Rho proteins family. FTIs affect the PI3-
K/Akt cell survival pathway. They also inhibit soft agar
growth of several breast cancer cells lines independent of
their Ras mutant status, probably through an alternative
target such as the protein RhoB which regulates receptor
trafficking and cell adhesion/motility. In total more than
100 polypeptides possess a CAAX sequence that poten-
tially can be farnesylated and such FTIs may have multiple
targets that may be inhibited to produce a net antiprolif-
erative effect or apoptosis [32]. As expected in the trans-
formed SaOs-2 cellular model used in these data, few
apoptotic cells have been noted following FTI treatment.
However, a high percentage of apoptosis has been noted
in our experiments only if FTI treated cells were previously
transduced by p53HRCaax. Our results confirmed the
data reported by Nielsen et al. that combination therapy
with a replication-deficient recombinant adenovirus,
which expresses the human p53, and an FTI have synergis-
tic or additive antiproliferative effects on a panel of tumor
cells in vitro [33].
Conclusion
This work has been performed to find application in gene
therapy protocols including, amongst others, i) the poten-
tial for inducing the activation so that the function of an
ectopic protein at a defined moment and ii) the safety of
therapeutic gene expression for the cells being treated. For
this second purpose, integrating vectors could be con-
structed as a polycistronic vector. It would contain the
gene of interest and the gene encoding a chimeric pro-
apoptotic protein such as Bax, TRAIL or p53 such as what
is currently done with the HSV-tk strategy. Upon request,
if deleterious effect appears on gene modified cells such as
transformation of the gene modified cells, we could apply
FTI and so induce the death of the modified cells. The
combination of FTI which have antitumoral effect plus
the apoptosis of the newly transformed cells could allow
the destruction of the unwanted transformed cells. The
synergestic effect of the FTI and p53 induced apoptosisBMC Biotechnology 2006, 6:26 http://www.biomedcentral.com/1472-6750/6/26
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could be of greater interest than the HSV-tk strategy.
Undoubtedly, the challenge now is to tease apart the intri-
cate circuitry that controls the cellular location of pro-
apoptotic-proteins.
Methods
Reagents
Mouse monoclonal antibody p53 (Bp53-12) was from
Santa Cruz Biotechnology (TEBU, Le Perray en Yvelines,
F). FITC-conjugated mouse anti-human p53, mouse anti
human Bax, or p21waf1/CIP1 were purchased from BD Bio-
sciences/pharmingen (F). Rabbit anti human HDJ2 was
from Lab Vision Inc, (Fremont, CA). FITC-Peroxidase-
conjugated anti-rabbit and anti-mouse secondary anti-
bodies, the β-actin antobodies and a liquid alkaline phos-
phatase detection kit were from Sigma (F). Mitotraker Red
was obtained from Molecular Probes (Eugene, OR).
Cell culture
The 293 (a transformed human embryonic kidney cell
line) and SaOs-2 (human osteosarcoma p53-/-) cell lines
were obtained from the American Type Culture Collection
(Rockville, MD) and were maintained as monolayers at
37°C in a humidified 5%CO2 atmosphere in DMEM
medium supplemented with 10 % FCS.
Construction and preparation of adenoviral vectors
The different ADNc which had to be cloned into the ade-
noviral plasmid (pShuttle) have been obtained by PCR
amplification. The forward primer used for all the PCR
amplification was : 5' ATAAGAATGCGGCCGCCAT-
GGAGGAGCCGCAGTCAG. We generated PCR fragments
corresponding respectively to wt p53, P53HRCaax and
P53HRSaax by using as reverse primer :
5'CCCAAGCTTTCAGTCTGAGTCAGGCCCTTCTGTCTT-
GAACATGAG, 5' CCCAAGCTTTCAGGAGAG-
CACACACTTGCAGCTCATGCAGCCGGGGCCACTCTCA
TCAGGAGGGTTCAGCTTCCGCAGCTTGTGGTCTGAGT-
CAGGCCCTTCTGTCTTGAACATGAG and 5'
CCCAAGCTTTCAGGAGAGCACGCTCTTGCAGCTCAT-
GCAGCCGGGGCCACTCTCATCAGGAGGGTTCAGCT-
TCCGCAGCTTGTGGTCTGAGTCAGGCCCTTCTGTCTTG
AACATGAG. Replication-deficient (∆E1, E3) adenoviral
vectors expressing the different chimeric p53 or control
(Adp53wt, Adp53HRCaax, Adp53HRSaax, AdLuc) under
the transcriptional control of the CMV promoter were
constructed with the AdEasy System (Qbiogen, F) accord-
ing to the manufacturer's protocol. Initially, a PCR ampli-
fied Not1-HindIII fragment containing the different form
of p53 was subcloned into the Not1-HindIII-digested pAd
shuttle CMV to get shuttle vectors pAdp53wt,
pAdp53HRCaax and pAp53HRSaax. Replication-defective
adenoviruses (Adp53wt, Adp53HRCaax and
Adp53HRSaax) plus adenoviral vectors control AdLuc
(encoding luciferase) or AdeGFP (encoding enhanced
Green Fluorescence Protein) were produced by transfec-
tion of 293 cells with a single isolate of each recombinant
adenoviral vector, expanded, and purified as described
[34]. Viral titers were initially determined by optical
absorbance at 260 nm. All the viral DNA have been iso-
lated from the viral particles, amplified by PCR and
sequenced.
In vitro adenoviral transduction
At day 0, 105 cells were seeded in a six-well plate. At day 1,
one of the 6 wells was trypsinated and the cells were
counted. This information was used to infect each cell line
at the desired multiplicity of infection (MOI). Transduc-
tions were in 5% CO2 incubators at 37°C for 1 hr using
500 µl infection medium (the same medium used for each
cell line + 2 % FBS) with agitation. Pilot experiments with
AdeGFP determined the optimal MOI for the SaOs-2 cells.
In these experiments (data not shown) all cells became
GFP positive, without manifesting toxicity, for up to 7
days after infection at a MOI of 100:1.
Immunoblotting
Cells were seeded in 35 mm dishes and grown to approx.
50 % confluence before transduction. Total protein
extracts were prepared 48 hrs post transduction, by lysing
the cultures in 150 µl lysis buffer containing 1% NP40,
0,1% SDS, 5 mM DTT and 1 mM PMSF for one hr on ice.
Lysates were centrifuged at 13000 rpm for 5 min to
remove nuclei and precipitates. Samples containing 80 µg
total cellular protein were subjected to 12,5 % SDS-PAGE
and transferred to a nitrocellulose membrane (Amersham
Biotech, F). Membranes were blocked for 1 hr at room
temperature in TBST-0.1% Tween 20/5% non-fat milk
then incubated overnight with antibodies directed against
β-actin (1:10,000), Bax (1:500), p53 (1:500), p21waf1/CIP1
(1: 500), or HDJ2 (1:1000). For signal detection the sec-
ondary mouse or rabbit antibody was used at a dilution of
1:10,000. Finally the blots were washed and developed
using enhanced chemiluminescence (Amersham Biotech,
F) according to the manufacturer's protocol and exposed
to radiographic films (Eastman Kodak).
Immunofluorescence and microscopy
For fluorescence analyses cells were washed twice with
PBS and fixed for 5 min at room temperature in PBS con-
taining 3,7% formaldehyde. The cells were then permea-
bilized with 0,2% Triton X-100 in PBS for 5 min at room
temperature. After repeated washes with PBS, cells were
incubated with FITC-conjugated mouse anti-human p53
antibody or appropriate controls for 1 hr, washed twice
with PBS and finally examined with a Leitz fluorescence
microscope. To stain the mitochondria (MT), cells were
incubated with 250 nM Mitotracker Red in pre-warmed
full medium for 30 min at 37°C and then washed twice
with full medium.BMC Biotechnology 2006, 6:26 http://www.biomedcentral.com/1472-6750/6/26
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Transcriptional activation
SaOs-2 cells were plated at 105 cells/35 mm tissue culture
dish. 24 hr later cells that had reached 60–80% conflu-
ence were co-transfected with 1 µg p53SREluc and 3 µg
preniliaLuc (rluc) reporter plasmids (PGL2 Promega).
P53SRELuc plasmid contains two copies of the p53 bind-
ing site (GC3p53 element) upstream of the HSV-tk pro-
moter cloned upstream of the DNA encoding the firefly
luciferase (Luc) and a poly(A) addition signal. For all
transfections plasmid DNA were mixed with JetPEI as
described by the manufacturer. Six hr later the medium
was replaced with fresh medium and cells were trans-
duced by the different adenoviral vectors at a MOI of 100.
All experiments were performed in triplicate. After 48 hr
culture, cells were lysed in 100 µl reporter lysis buffer
(Promega). Ten µl aliquots of each cell lysate were added
to 90 µl luciferase assay substrate solution and reporter
activity was measured using a single photo channel in a
packard scintillation counter (Meriden, Conn). Each set of
experiments was repeated. The relative reporter gene
expression was calculated as a ratio of that with the adLuc
control, arbitrarily taken as 1. The mean and SD were cal-
culated from the two sets of experiments.
To demonstrate transcriptional activation by p53 proteins
ex vivo, Western analysis for p21waf1/CIP1 and Bax proteins
was performed using monoclonal antobodies. The proce-
dure used was as described above for p53 detection.
Growth curves
For vector sensitivity experiments cells were trypsinized
and seeded into 96 plates (104 cells per dish) and then
allowed to adhere for 24 hr. Cells were then incubated
with vectors for 1 hr; whilst untreated cells received an
identical manipulation without vector and mock infected
cells received an identical manipulation with the AdLuc
vector. Cells were washed once with PBS and then fresh
medium was added. Cell numbers were enumerated daily
using 3-(4,5-dimethythiazl-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)2H-tetrazolium inner salt
(MTT).
Apoptosis assay
Apoptosis was evaluated quantitatively by measuring
phosphatidylserine externalisation, an early apoptotic
alteration. This was performed by fluorescence staining
using the annexin V-FLUO staining kit (Roche, F) accord-
ing to the manufacturer's recommendations. The propor-
tion of annexin V stained cells was determined with FITC-
positive cells scored using a fluorescent microscope
(Olympus IX70). Images were recorded with a digital
SPOT camera.
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